Extracellular Vesicles in Amyotrophic Lateral Sclerosis.
Gavin McCluskeyKaren E MorrisonColette DonaghyFrederique ReneWilliam John DuddyStephanie DuguezPublished in: Life (Basel, Switzerland) (2022)
Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disease and is the most common adult motor neuron disease. The disease pathogenesis is complex with the perturbation of multiple pathways proposed, including mitochondrial dysfunction, RNA processing, glutamate excitotoxicity, endoplasmic reticulum stress, protein homeostasis and endosomal transport/extracellular vesicle (EV) secretion. EVs are nanoscopic membrane-bound particles that are released from cells, involved in the intercellular communication of proteins, lipids and genetic material, and there is increasing evidence of their role in ALS. After discussing the biogenesis of EVs, we review their roles in the propagation of pathological proteins in ALS, such as TDP-43, SOD1 and FUS, and their contribution to disease pathology. We also discuss the ALS related genes which are involved in EV formation and vesicular trafficking, before considering the EV protein and RNA dysregulation found in ALS and how these have been investigated as potential biomarkers. Finally, we highlight the potential use of EVs as therapeutic agents in ALS, in particular EVs derived from mesenchymal stem cells and EVs as drug delivery vectors for potential treatment strategies.
Keyphrases
- amyotrophic lateral sclerosis
- endoplasmic reticulum stress
- induced apoptosis
- mesenchymal stem cells
- drug delivery
- stem cells
- gene expression
- bone marrow
- umbilical cord
- mass spectrometry
- risk assessment
- human health
- oxidative stress
- binding protein
- cell therapy
- protein protein
- climate change
- high speed
- atomic force microscopy
- nucleic acid